Evidence map›Paper›PMID 31366953›Full record

ArticleThe Journal of antibiotics2019

Heterologous production of coryneazolicin in Escherichia coli.

Momoko Takuma, Mai Kuroha, Yuki Nagano, Issara Kaweewan, Hikaru Hemmi, Takanori Oyoshi, Shinya Kodani

Abstract read
PubMed Publisher
In one paragraph

Article in The Journal of antibiotics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Momoko TakumaGraduate School of Integrated Science and Technology, Shizuoka University, 836 Ohya, Suruga-ku, Shizuoka, 422-8529, Japan.
Mai KurohaGraduate School of Integrated Science and Technology, Shizuoka University, 836 Ohya, Suruga-ku, Shizuoka, 422-8529, Japan.
Yuki NaganoGraduate School of Integrated Science and Technology, Shizuoka University, 836 Ohya, Suruga-ku, Shizuoka, 422-8529, Japan.
Issara KaweewanGraduate School of Science and Technology, Shizuoka University, 836 Ohya, Suruga-ku, Shizuoka, 422-8529, Japan.
Hikaru HemmiFood Research Institute, NARO, 2-1-12 Kannondai, Tsukuba, Ibaraki, 305-8642, Japan.
Takanori OyoshiGraduate School of Integrated Science and Technology, Shizuoka University, 836 Ohya, Suruga-ku, Shizuoka, 422-8529, Japan.
Shinya KodaniGraduate School of Integrated Science and Technology, Shizuoka University, 836 Ohya, Suruga-ku, Shizuoka, 422-8529, Japan. kodani.shinya@shizuoka.ac.jp.ORCID http://orcid.org/0000-0002-6792-1184

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coryneazolicin is a plantazolicin family peptide, belonging to linear azole-containing peptides (LAPs). Although coryneazolicin was previously synthesized by in vitro experiments, its biological activity has not been evaluated. In this report, the heterologous production of coryneazolicin was accomplished to obtain enough coryneazolicin for biological activity tests. The structure of coryneazolicin was confirmed by ESI-MS and NMR analyses. The biological activity tests indicated that coryneazolicin possessed potent antibacterial activity and cytotoxicity. Although antibacterial activity of plantazolicin was previously reported, cytotoxicity was newly found in coryneazolicin among plantazolicin type peptides. In addition, we revealed that coryneazolicin induced apoptosis on HCT116 and HOS cancer cell lines.

Indexed as

Anti-Bacterial AgentsAntineoplastic AgentsBacteriaCell Line, TumorCell SurvivalEscherichia coliHumansPeptidesProtein ConformationAnti-Bacterial AgentsAntineoplastic AgentsPeptides

Identifiers

PMID31366953

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.